1. Home
  2. TNXP vs ELME Comparison

TNXP vs ELME Comparison

Compare TNXP & ELME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

N/A

Current Price

$13.47

Market Cap

199.7M

Sector

Health Care

ML Signal

N/A

Logo Elme Communities

ELME

Elme Communities

N/A

Current Price

$1.66

Market Cap

191.9M

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
TNXP
ELME
Founded
2007
1960
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
199.7M
191.9M
IPO Year
2008
1994

Fundamental Metrics

Financial Performance
Metric
TNXP
ELME
Price
$13.47
$1.66
Analyst Decision
Hold
Analyst Count
0
4
Target Price
N/A
$12.67
AVG Volume (30 Days)
425.9K
653.2K
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
707.44%
EPS Growth
91.75
N/A
EPS
N/A
N/A
Revenue
$13,107,000.00
$206,360,000.00
Revenue This Year
$558.11
$5.03
Revenue Next Year
$38.29
$4.31
P/E Ratio
N/A
N/A
Revenue Growth
29.85
N/A
52 Week Low
$9.40
$1.26
52 Week High
$34.00
$17.68

Technical Indicators

Market Signals
Indicator
TNXP
ELME
Relative Strength Index (RSI) 59.03 61.52
Support Level $11.98 $1.46
Resistance Level $13.36 $2.06
Average True Range (ATR) 0.79 0.02
MACD 0.09 0.01
Stochastic Oscillator 60.55 87.50

Price Performance

Historical Comparison
TNXP
ELME

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About ELME Elme Communities

Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. It derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Elme Communities' tenants are banking, consulting, law, and financial services firms. The company operates in a single reportable segment which includes the ownership, development, redevelopment and acquisition of apartment communities.

Share on Social Networks: